{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:44Z","timestamp":1786988084639,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejogrb.2020.10.042","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T20:26:12Z","timestamp":1603398372000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Implications of non-invasive prenatal testing for identifying and managing high-risk pregnancies"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-2106","authenticated-orcid":false,"given":"Abi","family":"Merriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Alberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Abdel-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2020.10.042_bib0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(97)02174-0","article-title":"Presence of fetal DNA in maternal plasma and serum","volume":"350","author":"Dennis Lo","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/uog.17483","article-title":"ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice","volume":"49","author":"Salomon","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0015","series-title":"Routine antenatal anti-D prophylaxis for woment who are rhesus D negative (TA156)","year":"2008"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/pd.1700","article-title":"Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast","volume":"27","author":"Alberry","year":"2007","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0025","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/301800","article-title":"Quantitative analysis of fetal DNA in maternal plasma and serum: Implications for noninvasive prenatal diagnosis","volume":"62","author":"Lo","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/302205","article-title":"Rapid clearance of fetal DNA from maternal plasma","volume":"64","author":"Dennis Lo","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ajog.2003.12.019","article-title":"Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia","volume":"190","author":"Levine","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0040","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0140-6736(05)60395-9","article-title":"Maternal plasma fetal DNA as a marker for preterm labour","volume":"352","author":"Leung","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/uog.18993","article-title":"Association Between Fetal Fraction on Cell-Free DNA Testing and First-Trimester Markers for Pre-eclampsia","volume":"52","author":"Rolnik","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/clinchem\/48.2.353","article-title":"Increased cell-free fetal DNA in plasma of two women with invasive placenta","volume":"48","author":"Sekizawa","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/pd.788","article-title":"Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients","volume":"24","author":"Farina","year":"2004","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0060","first-page":"191","article-title":"Cell-free total and fetal DNA in first trimester maternal serum and subsequent development of preeclampsia","volume":"34","author":"Silver","year":"2017","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajog.2008.07.063","article-title":"Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction","volume":"200","author":"Alberry","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0070","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/pd.4119","article-title":"Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma","volume":"33","author":"Wang","year":"2013","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000346806","article-title":"Maternal plasma cell-free fetal and maternal DNA at 11-13 weeks\u2019 gestation: Relation to fetal and maternal characteristics and pregnancy outcomes","volume":"33","author":"Poon","year":"2013","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0080","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/pd.4940","article-title":"Absolute first trimester cell-free DNA levels and their associations with adverse pregnancy outcomes","volume":"36","author":"Thurik","year":"2016","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40291-016-0245-9","article-title":"Cell-Free Fetal DNA for the Prediction of Pre-Eclampsia at the First and Second Trimesters: A Systematic Review and Meta-Analysis","volume":"21","author":"Contro","year":"2017","journal-title":"Mol Diagnosis Ther"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/clinchem\/45.2.184","article-title":"Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia","volume":"45","author":"Lo","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ajog.2009.05.025","article-title":"First-trimester maternal plasma cell-free fetal DNA and preeclampsia","volume":"201","author":"Sifakis","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/pd.2372","article-title":"Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction","volume":"29","author":"Illanes","year":"2009","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.placenta.2012.11.001","article-title":"Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications","volume":"34","author":"Kim","year":"2013","journal-title":"Placenta"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0120","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/pd.4093","article-title":"RASSF1A in maternal plasma as a molecular marker of preeclampsia","volume":"33","author":"Papantoniou","year":"2013","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0125","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.ajog.2014.10.404","article-title":"Relationship between 1st trimester fetal fraction of cell-free DNA from maternal plasma and preeclampsia in a large general pregnancy population","volume":"212","author":"Norton","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/clinchem\/47.1.137","article-title":"Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia","volume":"47","author":"Leung","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1081\/PRG-120002911","article-title":"The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia","volume":"21","author":"Zhong","year":"2002","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajog.2004.01.040","article-title":"Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia","volume":"191","author":"Cotter","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejogrb.2012.09.006","article-title":"Cell-free fetal DNA and adverse outcome in low risk pregnancies","volume":"166","author":"Stein","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/pd.1645","article-title":"Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia","volume":"27","author":"Crowley","year":"2007","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0155","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/clinchem\/48.4.650","article-title":"Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum","volume":"48","author":"Swinkels","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0160","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/pd.1897","article-title":"Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia","volume":"27","author":"Tsui","year":"2007","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0165","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1067\/mob.2001.109594","article-title":"Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia","volume":"184","author":"Zhong","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0170","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/clinchem\/48.12.2141","article-title":"Fetal DNA clearance from maternal plasma is impaired in preeclampsia","volume":"48","author":"Lau","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1373\/49.5.727","article-title":"The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia","volume":"49","author":"Ng","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0180","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1373\/clinchem.2004.037713","article-title":"Circulating Corticotropin-Releasing Hormone mRNA in Maternal Plasma: Relationship with Gestational Age and Severity of Preeclampsia","volume":"50","author":"Farina","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0185","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","article-title":"National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications","volume":"379","author":"Blencowe","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0190","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1530\/REP-17-0619","article-title":"Cell-free fetal DNA and spontaneous preterm birth","volume":"155","author":"Van Boeckel","year":"2018","journal-title":"Reproduction"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0195","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pd.3917","article-title":"High levels of fetal DNA are associated with increased risk of spontaneous preterm delivery","volume":"32","author":"Jakobsen","year":"2012","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ajog.2016.02.009","article-title":"Cell-free DNA fetal fraction and preterm birth","volume":"215","author":"Dugoff","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajog.2004.12.023","article-title":"High levels of fetal cell-free DNA in maternal serum: A risk factor for spontaneous preterm delivery","volume":"193","author":"Farina","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0210","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/pd.2838","article-title":"Free fetal DNA levels in patients at risk of preterm labour","volume":"31","author":"Illanes","year":"2011","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/uog.14666","article-title":"Fetal fraction of cell-free DNA in maternal plasma in the prediction of spontaneous preterm delivery","volume":"45","author":"Quezada","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0220","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/pd.1513","article-title":"A prospective analysis of cell-free fetal DNA concentration in maternal plasma as an indicator for adverse pregnancy outcome","volume":"26","author":"Bauer","year":"2006","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/pd.596","article-title":"Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction - A pilot study","volume":"23","author":"Caramelli","year":"2003","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0200360","article-title":"Maternal total cell-free DNA in preeclampsia and fetal growth restriction: Evidence of differences in maternal response to abnormal implantation","volume":"13","author":"Rafaeli-Yehudai","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejogrb.2020.10.042_bib0235","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pd.973","article-title":"Total cell-free DNA (\u03b2-globin gene) distribution in maternal plasma at the second trimester: A new prospective for preeclampsia screening","volume":"24","author":"Farina","year":"2004","journal-title":"Prenat Diagn"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520306813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520306813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:49:04Z","timestamp":1759556944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211520306813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["S0301211520306813"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.042","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of non-invasive prenatal testing for identifying and managing high-risk pregnancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}